IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
LAWRENCEVILLE, N.J. — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company known for its pioneering work in immunotherapy, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. A pre-recorded presentation featuring the company will be available on demand during this prestigious event, which will take place in New York. The management team at IMUNON is also slated to conduct in-person meetings with investors from September 8 to 10, 2025.
Details of the Conference Presentation
IMUNON's presentation will be accessible starting September 5, 2025, at 7:00 a.m. ET. The format will be a pre-recorded webcast, providing a comprehensive overview of the company's advancements and future prospects in the field of immunotherapy.
Accessing the Webcast
The webcast can be viewed for 90 days via the provided link or through the IMUNON website under the News & Investors section. IMUNON strongly encourages listeners to engage with the presentation to gain insights into their innovative treatments leveraging genetic technology.
About IMUNON and Its Advancements
IMUNON is at the forefront of developing unique treatment modalities that utilize non-viral DNA technology to encourage the body’s natural defenses against diseases. Their leading-edge approaches differentiate them from traditional therapies and promise safer, more effective treatments. One of their groundbreaking modalities, TheraPlas, focuses on delivering cytokines and therapeutic proteins directly into solid tumors, aiming to stimulate the immune response where it is most needed.
The second modality, PlaCCine, aims to deliver viral antigens capable of triggering significant immunological responses. IMUNON's flagship clinical program, IMNN-001, is tailored for treating advanced ovarian cancer. This DNA-based immunotherapy has successfully completed several clinical trials, including a Phase 2 trial, known as OVATION 2. The therapy instructs the body to produce crucial cancer-fighting molecules at the tumor site, bolstering the natural immune response.
Moreover, IMUNON is progressing with its COVID-19 booster vaccine, IMNN-101, having recently completed initial human trials. This reflects the company's commitment to harnessing its technologies to address a wide array of challenging health conditions.
Looking Ahead
IMUNON envisions continuing to innovate within the realm of plasmid DNA technology. Their efforts aim to enhance treatment options for patients dealing with difficult-to-treat diseases. As the company expands its capabilities, collaboration and partnership will be key components in achieving these ambitious goals.
Connect with IMUNON
For those interested in learning more, IMUNON encourages visits to their official website. They offer valuable information about their innovative technologies and ongoing projects, aimed at improving patient outcomes in oncology and beyond.
Frequently Asked Questions
What is the H.C. Wainwright Global Investment Conference?
The H.C. Wainwright Global Investment Conference is a premier marketplace for investors and companies to connect, with presentations from a range of innovative firms in biotech and other sectors.
What is the focus of IMUNON?
IMUNON is dedicated to developing novel DNA-mediated immunotherapies designed for various difficult-to-treat diseases, utilizing advanced genetic technologies.
When will the pre-recorded presentation be available?
The presentation will be available on demand starting September 5, 2025, at 7:00 a.m. ET.
What are IMUNON's key therapies?
IMUNON's key therapies include IMNN-001, targeting ovarian cancer, and IMNN-101, a COVID-19 booster vaccine currently in development.
How can I get more information about IMUNON?
To obtain further details, you can visit IMUNON's official website or reach out directly via their contact information listed there.
